Axogen, Inc. (AXGN)

Axogen's stock experienced significant movement in the past six months, driven by financial results and regulatory milestones. The stock increased by 28.5% between January 1st, 2026, and May 9th, 2026. Key events include the FDA approval of the Biologics License Application (BLA) for Avance® in December 2025, the completion of an upsized public offering in January 2026, the report of Fourth Quarter and Full-Year 2025 financial results in February 2026, and the report of strong First Quarter 2026 financial results in April 2026. Analysts have generally maintained a "Moderate Buy" consensus rating for AXGN, but there have been reports of insider selling.

Based on the available information, there is no explicit indication of significant demand seasonality for Axogen's products and services. The nature of peripheral nerve injuries suggests a relatively consistent need for repair solutions throughout the year rather than seasonal fluctuations.

Axogen, Inc. is a medical technology company focused on developing and commercializing surgical solutions for peripheral nerve damage, operating within the Healthcare sector, specifically in the Medical Devices and Medical Specialties industries. The company's core business revolves around innovative biologic and engineered products designed to address traumatic and iatrogenic nerve injuries, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix™, and Axotouch® Two-Point Discriminator.

Axogen markets its technologies across North America, Europe, Australia, and parts of Latin America, with products available in the United States, Canada, Germany, the United Kingdom, and Spain. The company's headquarters are in Alachua, Florida, with a corporate campus in Tampa, Florida, a global distribution center in Burleson, Texas, and a global processing center in Vandalia, Ohio.

Axogen generally maintains a positive brand reputation, primarily driven by its exclusive focus on peripheral nerve repair and its innovative, clinically proven product portfolio. The FDA approval of Avance Nerve Graft significantly bolstered its reputation. Analyst ratings consistently show a "Moderate Buy" consensus, reflecting confidence in the company's strategic advancements and product offerings.

Institutional investors hold a significant portion of Axogen's stock, with 211 institutional owners holding a total of 44,560,049 shares, representing approximately 80.29% of the stock. Key individual insider owners include Guido J. Neels, Joseph M. Mandato, Ew Healthcare Partners LP, James E. Flynn, and De Novo Ventures II LP, holding 2.78% of the stock.